Standard BioTools

Standard BioTools, Inc. (NASDAQ: LAB), formerly known as Fluidigm Corporation, envisions innovating technology to improve human health. Standard BioTools has established a mature standardized portfolio of next-generation technologies to help biomedical researchers develop drugs faster and better. As a leading solutions provider, the company leverages its proprietary mass cytometry and microfluidics technologies to deliver reliable and reproducible insights into health and disease, aiming to translate scientific discoveries into better disease solutions. Standard BioTools collaborates with world-leading academic, government, pharmaceutical, biotechnology, animal and plant research, and clinical laboratories, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.